Sparfloxacin - instructions for use, dose, side effects, contraindications

Clinical and pharmacological group: & nbsp

Quinolones / fluoroquinolones

Included in the formulation

Sparflo®

pills inwards

Dr. Reddy's Laboratories Ltd. India

Sparfloxacin

pills inwards

AVVA RUS, OJSC Russia

Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

VED

АТХ:

J.01.M.A Fluoroquinolones

J.01.M.A.09 Sparfloxacin

Pharmacodynamics:

The broad-spectrum antibacterial drug inhibits the synthesis of DNA by blocking DNA gyre, disrupting the cross-linking of DNA gaps, destroys the cytoplasm, cell wall and bacterial membranes. It acts on extra- and intracellularly located microorganisms.

Has a wide range of antibacterial activity against Gram-positive and Gram-negative bacteria, as well as anaerobic microflora and certain microorganisms: mycoplasma, rickettsia, ureaplasma.

Pharmacokinetics:

Bioavailability after ingestion, regardless of meal time, is 92%. The maximum concentration of the drug in the blood plasma is reached in 3-6 hours. The connection with plasma proteins is 45%, it penetrates into all tissues and organs, including leukocytes and alveolar macrophages.

The half-life is 15-20 hours.

It is metabolized and deactivated in the liver, eliminated by the kidneys - about 40% and 60% - with feces in the form of inactive metabolites. Up to 12% is removed during hemodialysis.

Indications:

It is used for the treatment of infectious and inflammatory diseases caused by sensitive microorganisms, both in acute and chronic stages of diseases.

ICD-10

I.A30-A49.A40 Streptococcal septicemia

I.A30-A49.A41 Other septicemia

X.J00-J06.J01 Acute Sinusitis

X.J10-J18.J15 Bacterial pneumonia, not elsewhere classified

X.J20-J22.J20 Acute bronchitis

X.J30-J39.J32 Chronic Sinusitis

X.J40-J47.J42 Chronic bronchitis, unspecified

XI.K65-K67.K65.0 Acute peritonitis

XI.K80-K87.K81.0 Acute cholecystitis

XI.K80-K87.K81.1 Chronic cholecystitis

XI.K80-K87.K83.0 Cholangitis

XII.L00-L08.L01 Impetigo

XII.L00-L08.L02 Abscess of skin, boil and carbuncle

XII.L00-L08.L03 Phlegmon

XII.L00-L08.L08.0 Pyoderma

XIV.N10-N16.N10 Acute tubulointerstitial nephritis

XIV.N10-N16.N11 Chronic tubulointerstitial nephritis

XIV.N30-N39.N30 Cystitis

XIV.N30-N39.N34 Urethritis and urethral syndrome

XIV.N40-N51.N41 Inflammatory diseases of the prostate

Contraindications:

Epilepsy, severe renal failure (creatinine clearance less than 20 ml / min), deficiency of glucose-6-phosphate dehydrogenase.

Individual intolerance.

Carefully:

Older patients with kidney hypofunction probability.

Pregnancy and lactation:The action category for fetus by FDA is C. Contraindicated in pregnancy and lactation.

Dosing and Administration:

Inside the first day: 400 mg, then 200 mg once a day.

The highest daily dose: 400 mg.

The highest single dose: 400 mg.

Side effects:

Central and peripheral nervous system: dizziness, headache, drowsiness, paresthesia in the hands, hallucinatory disorders, convulsions, decreased tactile sensitivity.

Cardiovascular system: rarely - tachycardia.

The system of hematopoiesis: neutropenia, thrombocytopenia, eosinophilia.

Metabolism: rarely - hypoglycemia.

Digestive system: dyspeptic disorders, diarrhea, increased activity of liver enzymes: AST, ALT.

Musculoskeletal: tendon lesions (children's age), muscle weakness, rarely - rhabdomyolysis.

Dysbacteriosis.

Allergic reactions.

Overdose:

Strengthening of side effects, primarily in relation to the central nervous system and the psyche: impaired consciousness, convulsive attacks like epipripeds.

Treatment is symptomatic.

Interaction:

With simultaneous use with theophylline, there is a decrease in convulsive activity.

Glucocorticoids increase the risk of rupture of tendons.

With the simultaneous use of vitamin K antagonists, hemorrhagic diathesis may develop.

Special instructions:

In the treatment of patients who have suffered a stroke or severe craniocerebral injury, convulsive activity increases.

Treatment sparfloxacin can begin, without waiting for the result of bacteriological studies of the sensitivity of pathogenic flora to antibiotics.

Given the possible complications of the central nervous system, patients are undesirable to drive cars and perform work in an unstable position of the body.

Instructions

Sparfloxacin (Sparfloxacinum)